The latest price target for Kronos Bio (NASDAQ:KRON) was reported by Piper Sandler on November 14, 2024. The analyst firm set a price target for $1.00 expecting KRON to rise to within 12 months (a possible 17.65% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Kronos Bio (NASDAQ:KRON) was provided by Piper Sandler, and Kronos Bio downgraded their neutral rating.

There is no last upgrade for Kronos Bio

The last downgrade for Kronos Bio Inc happened on November 14, 2024 when Piper Sandler changed their price target from $6 to $1 for Kronos Bio Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kronos Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kronos Bio was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Kronos Bio (KRON) rating was a downgraded with a price target of $6.00 to $1.00. The current price Kronos Bio (KRON) is trading at is $0.85, which is out of the analyst’s predicted range.